Erratum: “Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo”(Journal of Clinical Oncology(2019)Doi:10.1200/JCO.2004.11.070);Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2092-2100

  Lev, Dina Chelouche ^a   Onn, Amir ^a   Melinkova, Vladislava O ^a   Miller, Claudia ^a   Stone, Valerie ^a   Ruiz, Maribelis ^a   McGary, Eric C ^a   Ananthaswamy, Honnavara N ^a   Price, Janet E ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; GELATINASE A; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; VASCULOTROPIN; ALKYLATING AGENT; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; MELANOMA CELL; METASTASIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; EVALUATION; GENE EXPRESSION REGULATION; HUMAN; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MELANOMA; MICE; MICE, NUDE; SKIN NEOPLASMS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2942696482     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.19.01099     Document Type: Erratum

References (39)

1. Howe HL, Wingo PA, Thun MJ, et al: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824-842, 2001
2. Bevona C, Sober AJ: Melanoma incidence trends. Dermatol Clin 20:589-595, 2002
3. Sun W, Schuchter LM: Metastatic melanoma. Curr Treat Options Oncol 2:193-202, 2001
4. Koh HK: Cutaneous melanoma. N Engl J Med 325:171-182, 1991
5. Johnson TM, Yahanda AM, Chang AE, et al: Advances in melanoma therapy. J Am Acad Dermatol 38:731-741, 1998
6. Becker JC, Kampgen E, Brocker EB: Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 25:503-510, 2000
7. Cassel WA, Olkowski ZL, Murray DR: Immunotherapy in malignant melanoma. J Clin Oncol 17:1963, 1999
8. Crosby T, Fish R, Coles B, et al: Systemic treatments for metastatic cutaneous melanoma. Cochrane Database System Review CD0012152000
9. Chapman PB, Einhorn LH, Meyers MH, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
10. Middleton MR, Grob JJ, Aaronson N, et al: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
11. Middleton MR, Lorigan P, Owen J, et al: A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82:1158-1162, 2000
12. McMasters KM, Swetter SM: Current management of melanoma: Benefits of surgical staging and adjuvant therapy. J Surg Oncol 82: 209-216, 2003
13. Hersey P: Adjuvant therapy for high-risk primary and resected metastatic melanoma. Intern Med J 33:33-13, 2003
14. Skatrud PL: The impact of multiple drug resistance (MDR) proteins on chemotherapy and drug discovery. Prog Drug Res 58:99-131, 2002
15. Baguley BC: Novel strategies for overcoming multidrug resistance in cancer. Biodrugs 16: 97-103, 2002
16. Goldie JH: Drug resistance in cancer: A perspective. Cancer Metastasis Rev 20:63-68, 2001
17. Liem AA, Chamberlain MP, Wolf CR, et al: The role of signal transduction in cancer treatment and drug resistance. Eur J Surg Oncol 28:679-684, 2002
18. Tannock IF: Tumor physiology and drug resistance. Cancer Metastasis Rev 20:123-132, 2002
19. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627, 2002
20. Lev DC, Ruiz M, Mills L, et al: Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: A possible escape mechanism from chemotherapy. Mol Cancer Ther 2:753-763, 2003
21. Luca M, Huang S, Gershenwald JE, et al: Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J Pathol 151:1105-1113, 1997
22. Singh RK, Gutman M, Radinsky R, et al: Ultraviolet-B irradiation promotes tumorigenic and metastatic primary cutaneous melanoma via induction of interleukin-8. Cancer Res 55:3669-3674, 1995
23. Institute of Laboratory Animal Resources Commission on Life Sciences, National Research Council: Guide for the Care and Use of Laboratory Animals. Washington. DC, National Academy Press, 1996
24. Huang S, Mills L, Mian B, et al: Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis tumor growth, and metastasis of human melanoma. Am J Pathol 161:125-134, 2002
25. Huang S, Jean D, Luca M, et al: Loss of AP-2 results in downregulation of c-kit and enhancement of melanoma tumorigenicity and metastasis. Embo J 17:4358-4369, 1998
26. Bruns CJ, Solorzano CC, Harbison M, et al: Blockade of the epidermal growth factor receptor by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935, 2000
27. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104:527-532, 2003
28. Satyamoorthy K, Li G, Gerrero MR, et al: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756-759, 2003
29. Ball NJ, Yohn JJ, Morelli JG, et al: Ras mutations in human melanoma: A marker of malignant progression. J Invest Dermatol 102: 285-290, 1994
30. Jafari M, Papp T, Kirchner S, et al: Analysis of ras mutations in human melanocytic lesions: Activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol 121:23-30, 1995
31. Hazan RB, Kang L, Roe S, et al: Vinculin is associated with the E-cadherin adhesion complex. J Biol Chem 272:32448-32453, 1997
32. Kashani-Sabet M, Leong SP, Sagebiel R, et al: Prognostic factors in malignant melanoma. Surg Oncol Clin N Am 6:599-623, 1997
33. Brunet A, Pages G, Pouyssegur J, et al: Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 9:3379-3387, 1994
34. Oka H, Chatani Y, Hoshno R, et al: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55:4182-4187, 1995
35. Ito Y, Sasaki Y, Horimoto M, et al: Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951-958, 1998
36. Sivaraman V, Wang HY, Nuovo G, et al: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99:1478-1483, 1997
37. Gioeli D, Mandell JW, Petroni GR, et al: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284, 1999
38. Smalley KS, Eisen TG: Farnesyl transferase inhibitor SCH66336 is cytostatic, proapoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 105:165-175, 2003
39. Jansen B, Schlagbauer-Wadl H, Kahr H, et al: Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A 96: 14019-14024, 1999